Gastrinomas: Advances in Diagnosis and Management

@article{Jensen2004GastrinomasAI,
  title={Gastrinomas: Advances in Diagnosis and Management},
  author={Robert T. Jensen},
  journal={Neuroendocrinology},
  year={2004},
  volume={80},
  pages={23 - 27}
}
  • R. Jensen
  • Published 1 October 2004
  • Medicine
  • Neuroendocrinology
Gastrinomas causing Zollinger-Ellison syndrome (ZES) are the most common functional, malignant pancreatic endocrine tumors. In this paper, the diagnosis and treatment of these tumors are reviewed, incorporating recent advances in each area. Furthermore, recent advances in their pathology, molecular pathogenesis, and aspects of their localization using somatostatin receptor scintigraphy, as well as their treatment are discussed. Recent data from our NIH prospective studies on patients with ZES… Expand
[Endocrine tumors of the stomach and duodenum (including gastrinoma) - management guidelines (recommended by the Polish Network of Neuroendocrine Tumors)].
TLDR
Polish guidelines for biochemical, pathological and localisation diagnosis, and therapeutic approaches, considering endoscopic and surgical treatment, pharmacological and radionuclide therapy are presented. Expand
Duodenal gastrinoma treated with endoscopic band ligation.
TLDR
A case of a duodenal gastrinoma that was treated with endoscopic band ligation (EBL) is reported, which is one of few data in which endoscopic therapy has been used to treat symptomatic duodentally gastrinomas. Expand
Tumor Detection in Syndromic NET: Zollinger-Ellison Syndrome
TLDR
A 40-year-old female, presented with recurrent epigastric pain and acid reflux, uncontrolled with proton pump inhibitors is presented with a MEN1-related ZES, hypothesized on the basis of early age of onset and the evidence of multifocal tumors within the pancreas and duodenum. Expand
Surgical management of Zollinger-Ellison syndrome; state of the art.
TLDR
All sporadic cases of ZES should be surgically explored (including duodenotomy) even with negative imaging results, because of the high likelihood of finding and removing a tumor for potential cure. Expand
Zollinger–Ellison Syndrome: Diagnosis and Management
TLDR
The management of ZES falls into two categories: the control of gastric acid hypersecretion and its clinical manifestations through the use of proton-pump inhibitors and the management of the tumor itself. Expand
Answer Wermer Syndrome and Zollinger-Ellison Syndrome
  • 2009
Z ollinger-Ellison Syndrome (ZES) is characterized by ulcer disease and dyspepsia due to inappropriate secretion of gastrin by neuroendocrine tumors called gastrinomas. Gastrinomas represent only aExpand
Surgery for gastrinoma.
TLDR
Investigation should include better defining the role of preoperative EUS and developing new, more sensitive techniques for preoperative localization for ZES, and define the appropriate indications for pancreaticoduodenectomy in ZES. Expand
[Pancreatic endocrine tumors - management guidelines (recommended by the Polish Network of Neuroendocrine Tumors)].
TLDR
These guidelines refer to biochemical and location diagnostics, including scintygraphy of somatostatin receptors, endoscopic ultrasonography and other anatomical and functional imaging methods, which determines further management of patients with PETs. Expand
Pancreatic islet cell carcinoma presenting with concurrent Cushing's and Zollinger-Ellison syndromes: case series and literature review.
Cushing's syndrome and Zollinger-Ellison syndrome occur occasionally as a result of neuroendocrine cancers. The concurrence of the two syndromes has been considered to confer a poor clinical andExpand
Long-term suppressive effect of octreotide on progression of metastatic gastrinoma with multiple endocrine neoplasia type 1: seven-year follow up.
TLDR
The case of a 30-year-old woman with a history of prolactinoma and primary hyperparathyroidism suggests the importance of investigating the Ki67/MIB1 index and SSTR expression in patients with metastatic gastrinoma. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 28 REFERENCES
Current surgical management of Zollinger-Ellison syndrome (ZES) in patients without multiple endocrine neoplasia-type 1 (MEN1).
TLDR
Operative techniques should always include duodenotomy and meticulous dissection of lymph nodes in the gastrinoma triangle, and postoperative evaluation should include secretin test because it is the most sensitive method to document cure and detect tumor recurrence. Expand
Molecular insights into gastrointestinal neuroendocrine tumours: importance and recent advances.
  • V. Corleto, G. delle Fave, R. Jensen
  • Medicine
  • Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • 2002
TLDR
There is an increased understanding of the molecular pathogenesis/changes in neuroendocrine tumours and this may identify important prognostic factors and possibly, new treatments. Expand
Management of the Zollinger–Ellison syndrome in patients with multiple endocrine neoplasia type 1
  • Jensen
  • Medicine
  • Journal of internal medicine
  • 1998
TLDR
Management of the Zollinger–Ellison syndrome in patients with multiple endocrine neoplasia type 1 (Minisymposium: MEN & VHL). Expand
Gastric Secretion in Zollinger-Ellison Syndrome: Correlation with Clinical Expression, Tumor Extent and Role in Diagnosis—A Prospective NIH Study of 235 Patients and a Review of 984 Cases in the Literature
TLDR
The aims of the study were to evaluate the sensitivity of proposed acid secretory criteria for the diagnosis of ZES, propose new criteria, evaluate the variability and methodology of gastric secretory testing, and correlate the symptoms and signs of Zes, tumor extent, and primary tumor size and location with the degree of Gastric acid hypersecretion. Expand
Growth of newly diagnosed, untreated metastatic gastrinomas and predictors of growth patterns.
TLDR
The growth rate of metastatic gastrinoma varies markedly in different patients and 26% demonstrate no growth, which needs to be considered in the determination of when and in whom antitumor therapy is initiated, as well as in the assessment of response to tumoricidal therapies. Expand
Prospective study of the antitumor efficacy of long‐term octreotide treatment in patients with progressive metastatic gastrinoma
TLDR
The purpose of the current study was to study prospectively the efficacy, safety, and effect on survival of long‐term treatment with octreotide in consecutive patients with progressive malignant gastrinoma. Expand
Zollinger‐Ellison Syndrome: Clinical Presentation in 261 Patients
TLDR
The initial presenting symptoms in 261 patients with Zollinger-Ellison syndrome (ZES) over a 25-year period were evaluated, finding that abdominal pain and diarrhea were the most common symptoms, present in 75% and 73% of patients, respectively. Expand
Prospective study of the clinical course, prognostic factors, causes of death, and survival in patients with long-standing Zollinger-Ellison syndrome.
  • F. Yu, D. Venzon, +4 authors R. Jensen
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1999
TLDR
Gastrinoma growth is now the main single determinant of long-term survival in ZES, with one half of patients dying a gastrinoma-related death and none an acid- related death. Expand
Determinants of metastatic rate and survival in patients with Zollinger-Ellison syndrome: a prospective long-term study.
TLDR
Survival was primarily determined by the presence of liver metastases, and the frequency of Liver metastases depends on the size and location of the primary tumor and on the Presence of MEN-1 at the initial presentation. Expand
Does the widespread use of proton pump inhibitors mask, complicate and/or delay the diagnosis of Zollinger–Ellison syndrome?
Proton pump inhibitors are potent acid suppressants which, at normal doses, can result in hypergastrinaemia in patients with idiopathic oesophageal reflux disease and in the control of symptoms inExpand
...
1
2
3
...